Introduction
gastric cancer
RECURRENCES, RECURRENCE, WEST, SECONDARY, STAGE III GASTRIC CANCER, GASTRIC CANCER
The prognosis of patients with gastric cancer is dismal once recurrence occurs after curative surgery. Optimal adjuvant treatments to avoid recurrence have been explored extensively, resulting in some differences in current standards of care between the West and Far East [JACCRO GC-07 is a randomized phase III study examining the superiority of S-1 plus docetaxel over S-1 monotherapy in the postoperative adjuvant setting for patients with pathologically Stage III gastric cancer who underwent D2 gastrectomy. Since the primary endpoint of 3-year relapse-free survival was met both at the second interim analysis [In this short communication, we report on overall survival (OS) and relapse-free survival (RFS) rates at 5 years after surgery, as the last two secondary endpoints in this trial. In addition, we sought to explore whether the addition of docetaxel had any preventive effects on late recurrences diagnosed > 3 years after randomization.